6 results about "Trypsin activity" patented technology

A composition for suppressing trypsin activity is disclosed. The composition contains a bacterium belonging to a genus Paraprevotella as an active ingredient.

The application discloses an amino-functionalized magnetic mesoporous nanomaterial and a preparation method and application thereof, and the nanomaterial is Fe3O4@nSiO2@TiO2@mSiO2-NH2; from inside to outside, the nanomaterial comprises a magnetite magnetic core, a dense silica layer, a titanium dioxide layer and an amino-functionalized mesoporous silica layer. The magnetic core is synthesized by a solvothermal method, the dense silica layer and the titanium dioxide layer are coated by adopting a sol-gel method in sequence, and finally the amino-functionalized mesoporous silica layer is modified by a co-condensation method. The material can protonate the surface amino group to form a local alkaline microenvironment under an acidic condition, can maintain trypsin activity, realizes synchronous performance of rapid enzymolysis of proteins and in-situ enrichment of phosphorylated peptides, and significantly shortens the enzymolysis time. The application has excellent enrichment selectivity for the phosphorylated peptides, the sensitivity reaches 10 fmol / μL, the enrichment capacity is about 100 mg / g, and is suitable for high-throughput quantitative analysis of phosphorylated proteins in complex biological samples.

The present application belongs to the field of biomedical detection technology, and particularly relates to a reaction solution for detecting trypsin-like transpeptidase activity and application thereof. The present application uses BAPNA as a specific substrate, which can produce a detectable signal change in the transpeptidation reaction, and a high-concentration amino group-glycine amide is added as a receptor molecule to enhance the transpeptidation reaction efficiency. Therefore, the present application solves the technical problem that the enzyme activity cannot be detected by the immunization method, has high reaction efficiency, stable and reliable detection process, shortened operation time (within 15 minutes), simple operation, strong practicability, can be used for evaluating the severity of acute allergic reaction, providing scientific guidance for the diagnosis of mast cell-related airway inflammation and mast cell activation syndrome, monitoring the effect of allergic treatment, and has clinical value in airway inflammation typing, differential diagnosis and efficacy monitoring through induced sputum or BAL fluid trypsin activity determination.

This disclosure provides large-scale processes for preparing a modulator of alpha-1 antitrypsin (AAT) activity that may be useful for treating alpha-1 antitrypsin deficiency (AATD), such as 4-(5-(4-fluorophenyl)-6-(tetrahydro-2H-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid (Compound 1), 3-[5-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo[2,3-f]indazol-7-yl]propanoic acid (Compound 2), or a pharmaceutically acceptable salt of any of the foregoing.

This invention provides a method for screening, separating, and identifying trypsin inhibitors, belonging to the field of biomedical technology. The invention first uses colorimetric sensor technology to rapidly identify samples with trypsin-inhibiting activity. Then, using affinity adsorption technology combined with liquid chromatography-mass spectrometry (LC-MS), specific components in the samples with trypsin-inhibiting activity can be identified. Specifically, trypsin is immobilized on Tp-Pa to form a TRY@Tp-Pa affinity chromatography carrier material. The extract to be screened is incubated with the affinity chromatography carrier material, and after removing the unadsorbed liquid, methanol is used to elute the eluent, which contains the bioactive compounds retained on TRY@Tp-Pa. These compounds are the potential active ingredients, and LC-MS is then used to identify the components. The method provided by this invention can efficiently and accurately detect trypsin activity and screen inhibitors, with high screening efficiency and a low false positive rate.

This invention discloses a composite hydrogel based on sodium alginate and citric acid, its preparation method, and its applications, belonging to the field of biomedical materials and polymer hydrogels. The composite hydrogel is formed by mixing two components, A and B, to form a gel. Component A contains an aqueous solution of sodium alginate and citric acid, while component B is a crosslinking agent solution containing soluble polyvalent cations. The polyvalent cations are selected from one or more combinations of calcium ions, barium ions, and strontium ions. This invention utilizes citric acid to competitively chelate metal cations with sodium alginate, effectively slowing down the gelation rate and optimizing the three-dimensional density of the gel, significantly improving the in-situ adhesion and sealing stability of the material. Simultaneously, the local slow-release of citric acid lowers the pH of the microenvironment to a slightly acidic range of 6.0-6.5, achieving non-competitive inhibition of trypsin activity.